Publication
Chronic hepatitis C treated with peginterferon alfa plus ribavirin in clinical practice
| dc.contributor.author | Velosa, J | |
| dc.contributor.author | Serejo, F | |
| dc.contributor.author | Bana, T | |
| dc.contributor.author | Redondo, I | |
| dc.contributor.author | Simão, A | |
| dc.contributor.author | Vale, A | |
| dc.contributor.author | Pires, S | |
| dc.contributor.author | Macedo, G | |
| dc.contributor.author | Marinho, R | |
| dc.contributor.author | Peixe, P | |
| dc.contributor.author | Sarmento, J | |
| dc.contributor.author | Matos, L | |
| dc.contributor.author | Calinas, F | |
| dc.contributor.author | Carvalho, A | |
| dc.contributor.author | Figueiredo, A | |
| dc.date.accessioned | 2013-03-12T15:09:59Z | |
| dc.date.available | 2013-03-12T15:09:59Z | |
| dc.date.issued | 2011 | |
| dc.description.abstract | BACKGROUND/AIMS: The role of genotype and viremia were retrospectively evaluated on sustained virological response (SVR) rates in routine clinical practice. METHODOLOGY: From 1907 patients with chronic hepatitis C proposed for treatment, we analysed 1380 (1124 naive and 256 treatment-experienced) with complete follow-up. Genotype and HCV RNA quantification were assayed by commercial tests. Viremia was considered high if >800,000IU/mL, and low if <400,000IU/mL. Liver fibrosis was staged in 614 patients. RESULTS: Genotype 1 was the most frequent (60%), followed by 3 (25%), 4 (9%) and 2 (2%); 3.2% had other or unclassified genotype. Genotype 1 was more prevalent in central Portugal and genotype 4 in the south. Viremia was =800,000IU/mL in 54.6% and <400,000IU/mL in 34.6% of the patients, particularly in genotype 2 (p<0.03) and 4 (p<0.001). Genotype non-1 had a significantly lower viral load (p=0.004). Mild or moderate fibrosis was present in 71.7% and bridging fibrosis or cirrhosis in 28.3%, with no differences among genotypes. Treatment was discontinued in 19.8%. SVR was achieved in 55.3% of naive and 36.3% of re-treated patients. CONCLUSIONS: Standard treatment of chronic hepatitis C in real-life achieves similar results obtained in clinical trials, despite differences of demographic and viral parameters. | por |
| dc.identifier.citation | Hepatogastroenterology. 2011 Jul-Aug;58(109):1260-6 | por |
| dc.identifier.issn | 0172-6390 | |
| dc.identifier.uri | http://hdl.handle.net/10400.10/883 | |
| dc.language.iso | eng | por |
| dc.peerreviewed | yes | por |
| dc.publisher | Update Medical Publishing | por |
| dc.subject | Chronic hepatitis C | por |
| dc.subject | Interferon-alpha | por |
| dc.subject | Ribavirin | por |
| dc.subject | Hepatite C | por |
| dc.title | Chronic hepatitis C treated with peginterferon alfa plus ribavirin in clinical practice | por |
| dc.type | journal article | |
| dspace.entity.type | Publication | |
| oaire.citation.conferencePlace | Athens | por |
| oaire.citation.endPage | 1266 | por |
| oaire.citation.startPage | 1260 | por |
| oaire.citation.title | Hepatogastroenterology | por |
| oaire.citation.volume | 58 | por |
| rcaap.rights | openAccess | por |
| rcaap.type | article | por |